

# Matteo Lambertini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8041626/publications.pdf>

Version: 2024-02-01

255  
papers

8,638  
citations

61945

43  
h-index

66879

78  
g-index

263  
all docs

263  
docs citations

263  
times ranked

9014  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer and fertility preservation: international recommendations from an expert meeting. BMC Medicine, 2016, 14, 1.	2.3	521
2	Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Annals of Oncology, 2018, 29, 1497-1508.	0.6	305
3	ESHRE guideline: female fertility preservation. Human Reproduction Open, 2020, 2020, hoaa052.	2.3	282
4	Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. Journal of Clinical Oncology, 2018, 36, 1981-1990.	0.8	268
5	Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. European Journal of Cancer, 2020, 139, 43-50.	1.3	267
6	Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology, 2020, 31, 1664-1678.	0.6	243
7	Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival. JAMA - Journal of the American Medical Association, 2015, 314, 2632.	3.8	180
8	Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Annals of Oncology, 2015, 26, 2408-2419.	0.6	178
9	Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials. Cancer Treatment Reviews, 2014, 40, 675-683.	3.4	169
10	Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies. Cancer Treatment Reviews, 2016, 49, 65-76.	3.4	167
11	Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective. ESMO Open, 2020, 5, e000759.	2.0	161
12	Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Annals of Oncology, 2019, 30, 1601-1612.	0.6	146
13	Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. Journal of the National Cancer Institute, 2018, 110, 426-429.	3.0	143
14	Follow-up strategies for women treated for early breast cancer. The Cochrane Library, 2016, 2016, CD001768.	1.5	138
15	Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. Annals of Oncology, 2019, 30, 1784-1795.	0.6	138
16	Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. International Journal of Women's Health, 2019, Volume 11, 431-437.	1.1	117
17	Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncology, The, 2021, 22, e303-e313.	5.1	116
18	Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. European Journal of Cancer, 2022, 160, 243-260.	1.3	93

#	ARTICLE	IF	CITATIONS
19	Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. <i>Annals of Oncology</i> , 2018, 29, 237-243.	0.6	90
20	The five "W's" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 112-128.	2.0	87
21	Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. <i>Breast</i> , 2017, 35, 142-150.	0.9	87
22	Targeted agents for cancer treatment during pregnancy. <i>Cancer Treatment Reviews</i> , 2015, 41, 301-309.	3.4	84
23	Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application. <i>Cancer Treatment Reviews</i> , 2019, 72, 65-77.	3.4	83
24	Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. <i>European Journal of Cancer</i> , 2017, 71, 25-33.	1.3	79
25	Twenty years of anti-HER2 therapy-associated cardiotoxicity. <i>ESMO Open</i> , 2016, 1, e000073.	2.0	76
26	Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2017, 57, 8-15.	3.4	75
27	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. <i>Breast</i> , 2018, 42, 41-49.	0.9	75
28	Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2019, 111, 86-94.	3.0	73
29	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680.	5.1	73
30	Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review. <i>Cancer Treatment Reviews</i> , 2016, 45, 38-45.	3.4	71
31	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 3293-3305.	0.8	70
32	Pregnancy After Breast Cancer in Patients With Germline <i>BRCA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2020, 38, 3012-3023.	0.8	69
33	Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art. <i>Current Opinion in Oncology</i> , 2017, 29, 243-252.	1.1	68
34	Fertility and pregnancy issues in BRCA -mutated breast cancer patients. <i>Cancer Treatment Reviews</i> , 2017, 59, 61-70.	3.4	68
35	How I treat metastatic triple-negative breast cancer. <i>ESMO Open</i> , 2019, 4, e000504.	2.0	59
36	Breast cancer treatment-induced cardiotoxicity. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1021-1038.	1.0	58

#	ARTICLE	IF	CITATIONS
37	Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2020, 126, 65-73.	1.3	58
38	Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTO (BIG 1-06) and ALTO (BIG) Tj ETQp00 0 rgB57Overlock	2.0	47
39	Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTO sub-study (BIG 1-06). <i>Breast Cancer Research and Treatment</i> , 2018, 168, 631-638.	1.1	49
40	Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. <i>ESMO Open</i> , 2018, 3, e000361.	2.0	49
41	Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 574669.	1.3	48
42	Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103365.	2.0	48
43	State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature. <i>Cancer Treatment Reviews</i> , 2017, 57, 50-57.	3.4	47
44	EUropean REcommendations for female FERtility preservation (EU-REFER): A joint collaboration between oncologists and fertility specialists. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 233-240.	2.0	47
45	The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration. <i>ESMO Open</i> , 2021, 6, 100058.	2.0	47
46	Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?. <i>Translational Oncology</i> , 2020, 13, 100811.	1.7	46
47	Radiation therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: a view of the nation's young oncologists. <i>ESMO Open</i> , 2020, 5, e000779.	2.0	46
48	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. <i>British Journal of Cancer</i> , 2016, 115, 1471-1478.	2.9	45
49	Strategies for fertility preservation in young early breast cancer patients. <i>Breast</i> , 2014, 23, 503-510.	0.9	42
50	It Is Time to Talk About Fertility and Immunotherapy. <i>Oncologist</i> , 2020, 25, 277-278.	1.9	42
51	Exclusive endocrine therapy or partial breast irradiation for women aged ≥70 years with luminal A-like early stage breast cancer (NCT04134598 - EUROPA): Proof of concept of a randomized controlled trial comparing health related quality of life by patient reported outcome measures. <i>Journal of Geriatric Oncology</i> , 2021, 12, 182-189.	0.5	42
52	Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study. <i>Breast</i> , 2018, 41, 51-56.	0.9	41
53	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1458-1467.	5.1	41
54	Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. <i>Human Reproduction</i> , 2022, 37, 954-968.	0.4	41

#	ARTICLE	IF	CITATIONS
55	Update on fertility preservation in young women undergoing breast cancer and ovarian cancer therapy. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 98-107.	0.9	40
56	Adjuvant trastuzumab: a 10-year overview of its benefit. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 61-74.	1.1	40
57	Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 575.	1.3	40
58	Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 27-37.	1.1	40
59	Lucitanib for the Treatment of HR+/HER2 <sup>+</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , 2020, 26, 354-363.	3.2	40
60	Anti-müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. <i>Human Reproduction Update</i> , 2022, 28, 417-434.	5.2	40
61	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. <i>European Journal of Cancer</i> , 2017, 71, 34-42.	1.3	39
62	A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 161-171.	1.1	39
63	Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate?. <i>Oncologist</i> , 2015, 20, 1233-1235.	1.9	38
64	Beyond fertility preservation: role of the oncofertility unit in the reproductive and gynecological follow-up of young cancer patients. <i>Human Reproduction</i> , 2019, 34, 1462-1469.	0.4	38
65	Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591982771.	1.4	38
66	Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities. <i>JCO Oncology Practice</i> , 2020, 16, e1304-e1314.	1.4	38
67	Update on the Management of Breast Cancer during Pregnancy. <i>Cancers</i> , 2020, 12, 3616.	1.7	37
68	Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic. <i>British Journal of Cancer</i> , 2021, 125, 1486-1493.	2.9	37
69	Immunotherapy for cancer treatment during pregnancy. <i>Lancet Oncology</i> , The, 2021, 22, e550-e561.	5.1	37
70	Biology, staging, and treatment of breast cancer during pregnancy: reassessing the evidences. <i>Cancer Biology and Medicine</i> , 2018, 15, 6.	1.4	36
71	Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data. <i>Journal of Clinical Oncology</i> , 2021, 39, 2016-2024.	0.8	36
72	Anti-müllerian hormone: determination of ovarian reserve in early breast cancer patients. <i>Endocrine-Related Cancer</i> , 2014, 21, R51-R65.	1.6	35

#	ARTICLE	IF	CITATIONS
73	Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTO (BIG 2-06) randomized clinical trial. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 103-114.	1.1	34
74	Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA. <i>Journal of Oncology</i> , 2020, 2020, 1-10.	0.6	34
75	Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments. <i>European Journal of Cancer</i> , 2021, 144, 310-316.	1.3	34
76	Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1258-1267.	0.8	33
77	Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021, 148, 76-91.	1.3	33
78	Tamoxifen Exposure during Pregnancy: A Systematic Review and Three More Cases. <i>Breast Care</i> , 2020, 15, 148-156.	0.8	32
79	Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 629-649.	1.1	31
80	Call for ensuring cancer care continuity during COVID-19 pandemic. <i>ESMO Open</i> , 2020, 5, e000783.	2.0	31
81	VISTA: A Promising Target for Cancer Immunotherapy?. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 185-200.	2.7	31
82	Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment. <i>Cancers</i> , 2021, 13, 4013.	1.7	31
83	Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study. <i>Clinical Breast Cancer</i> , 2017, 17, 601-610.e2.	1.1	30
84	The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients. <i>BMC Cancer</i> , 2017, 17, 346.	1.1	30
85	T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study. <i>Clinical Breast Cancer</i> , 2020, 20, e181-e187.	1.1	30
86	Reproductive issues in carriers of germline pathogenic variants in the BRCA1/2 genes: an expert meeting. <i>BMC Medicine</i> , 2021, 19, 205.	2.3	30
87	Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer. <i>Breast</i> , 2018, 37, 142-147.	0.9	29
88	Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in young BRCA-mutated breast cancer patients. <i>Reproductive BioMedicine Online</i> , 2019, 38, 835-844.	1.1	29
89	Clinical utility of genomic signatures in young breast cancer patients: a systematic review. <i>Npj Breast Cancer</i> , 2020, 6, 46.	2.3	29
90	Utility of gonadotropin-releasing hormone agonists for fertility preservation in women receiving chemotherapy: pros and cons. <i>Fertility and Sterility</i> , 2020, 114, 725-738.	0.5	29

#	ARTICLE	IF	CITATIONS
91	Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. Expert Opinion on Investigational Drugs, 2022, 31, 567-591.	1.9	29
92	Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy as a strategy to reduce ovarian failure in early breast cancer patients. Annals of Oncology, 2015, 26, vi1.	0.6	28
93	Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak. European Journal of Clinical Investigation, 2020, 50, e13315.	1.7	28
94	Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review. ESMO Open, 2021, 6, 100276.	2.0	28
95	Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study. Oncologist, 2015, 20, 880-889.	1.9	26
96	Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations. Npj Breast Cancer, 2018, 4, 23.	2.3	26
97	Radiomics and "radiomics" in cancer immunotherapy: a guide for clinicians. Critical Reviews in Oncology/Hematology, 2020, 154, 103068.	2.0	26
98	Preimplantation genetic testing for carriers of BRCA1/2 pathogenic variants. Critical Reviews in Oncology/Hematology, 2021, 157, 103201.	2.0	26
99	Nail involvement as a negative prognostic factor in biological therapy for psoriasis: a retrospective study. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 843-846.	1.3	25
100	Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D. Breast, 2022, 65, 32-40.	0.9	25
101	Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2022, 191, 269-275.	1.1	24
102	The impact of COVID-19 on oncology professionals' one year on: lessons learned from the ESMO Resilience Task Force survey series. ESMO Open, 2022, 7, 100374.	2.0	24
103	The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer. Frontiers in Oncology, 2021, 11, 690320.	1.3	23
104	Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?. Clinical Medicine Insights Reproductive Health, 2019, 13, 117955811982839.	3.9	22
105	Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer. Breast Cancer Research, 2019, 21, 25.	2.2	22
106	Debated Role of Ovarian Protection With Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Women With Cancer. Journal of Clinical Oncology, 2017, 35, 804-805.	0.8	20
107	Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review. Clinical Medicine Insights Reproductive Health, 2019, 13, 117955811986458.	3.9	20
108	Fertility, sexuality and cancer in young adult women. Current Opinion in Oncology, 2019, 31, 259-267.	1.1	20

#	ARTICLE	IF	CITATIONS
109	Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in <i>BRCA1/2</i> : A Review of Secondary Prevention Guidelines. <i>Journal of Oncology</i> , 2020, 2020, 1-13.	0.6	20
110	Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer. <i>Cancer</i> , 2021, 127, 1021-1028.	2.0	20
111	Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 462-470.	3.0	20
112	Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1391-1405.	1.1	19
113	Protecting Ovaries During Chemotherapy Through Gonad Suppression. <i>Obstetrics and Gynecology</i> , 2015, 126, 901.	1.2	19
114	The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II. <i>ESMO Open</i> , 2021, 6, 100199.	2.0	19
115	Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 159, 154-166.	1.3	19
116	Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. <i>European Journal of Cancer</i> , 2022, 171, 64-74.	1.3	19
117	Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis. <i>International Journal of Cancer</i> , 2022, 151, 1860-1873.	2.3	19
118	Exploring the safety of chemotherapy for treating breast cancer during pregnancy. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1395-1408.	1.0	18
119	Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13604.	1.7	18
120	Pegfilgrastim administration after 24 or 72 or 96h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial. <i>Supportive Care in Cancer</i> , 2016, 24, 1285-1294.	1.0	17
121	Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 4.	1.3	17
122	Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1799-1817.	1.4	16
123	Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis. <i>Breast</i> , 2017, 33, 104-108.	0.9	16
124	Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 62, 123-132.	3.4	16
125	Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis. <i>ESMO Open</i> , 2020, 5, e000842.	2.0	16
126	Fertility counseling of young breast cancer patients. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 1, S68-80.	0.6	16



#	ARTICLE	IF	CITATIONS
127	Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate. <i>Annals of Oncology</i> , 2022, 33, 347-349.	0.6	16
128	Management of young women with early breast cancer. <i>ESMO Open</i> , 2018, 3, e000458.	2.0	15
129	Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6045.	1.8	15
130	Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients. <i>Breast Cancer: Basic and Clinical Research</i> , 2020, 14, 117822342095417.	0.6	15
131	Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network. <i>ESMO Open</i> , 2021, 6, 100104.	2.0	15
132	CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis. <i>ESMO Open</i> , 2021, 6, 100091.	2.0	15
133	Emerging issues related to COVID-19 vaccination in patients with cancer. <i>Oncology and Therapy</i> , 2021, , 1-11.	1.0	15
134	Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2022, 114, 400-408.	3.0	15
135	Chemotherapy-induced premature ovarian failure and its prevention in premenopausal breast cancer patients. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 5-7.	0.6	14
136	Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Breast</i> , 2018, 39, 14-18.	0.9	14
137	CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13535.	1.7	14
138	Impact of HIV infection on baseline characteristics and survival of women with breast cancer. <i>Aids</i> , 2021, 35, 605-618.	1.0	14
139	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 979-987.	3.0	14
140	Methods of controlled ovarian stimulation for embryo/oocyte cryopreservation in breast cancer patients. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 47-59.	0.6	13
141	Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 181-189.	2.3	13
142	Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. <i>Npj Breast Cancer</i> , 2021, 7, 16.	2.3	13
143	How I perform fertility preservation in breast cancer patients. <i>ESMO Open</i> , 2021, 6, 100112.	2.0	13
144	Gender-specific aspects related to type of fertility preservation strategies and access to fertility care. <i>ESMO Open</i> , 2020, 5, e000771.	2.0	13

#	ARTICLE	IF	CITATIONS
145	Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy. <i>European Journal of Cancer</i> , 2022, 173, 113-122.	1.3	13
146	How reliable are the available safety data on hormonal stimulation for fertility preservation in young women with newly diagnosed early breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 773-774.	1.1	12
147	Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. <i>International Journal of Cancer</i> , 2020, 147, 160-169.	2.3	12
148	Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study. <i>British Journal of Cancer</i> , 2020, 122, 1611-1617.	2.9	12
149	T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. <i>ESMO Open</i> , 2021, 6, 100099.	2.0	12
150	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	1.7	12
151	Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis. <i>ESMO Open</i> , 2022, 7, 100501.	2.0	12
152	Stevens-Johnson syndrome after treatment with bendamustine. <i>Leukemia Research</i> , 2012, 36, e153-e154.	0.4	11
153	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , 2016, 1, e000107.	2.0	11
154	New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients. <i>Cancer Treatment Reviews</i> , 2016, 42, 18-23.	3.4	11
155	Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3363-3372.	1.0	11
156	Radiation therapy for young women with early breast cancer: Current state of the art. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 137, 143-153.	2.0	11
157	Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 99.	2.3	11
158	How to Protect Ovarian Function before and during Chemotherapy?. <i>Journal of Clinical Medicine</i> , 2021, 10, 4192.	1.0	11
159	The neglected members of the family: non-BRCA mutations in the Fanconi anemia/BRCA pathway and reproduction. <i>Human Reproduction Update</i> , 2022, 28, 296-311.	5.2	11
160	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. <i>European Journal of Cancer</i> , 2022, 170, 10-16.	1.3	11
161	Gonadotropin-releasing hormone analogs for ovarian function protection during chemotherapy in young early breast cancer patients: the last piece of the puzzle?. <i>Annals of Oncology</i> , 2017, 28, 1683-1685.	0.6	10
162	Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?. <i>ESMO Open</i> , 2018, 3, e000324.	2.0	10

#	ARTICLE	IF	CITATIONS
163	Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel. <i>Cancers</i> , 2022, 14, 1022.	1.7	10
164	Pharmacotherapy to protect ovarian function and fertility during cancer treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 739-742.	0.9	9
165	Viable Options for Fertility Preservation in Breast Cancer Patients: A Focus on Latin America. <i>Revista De Investigacion Clinica</i> , 2017, 69, 103-113.	0.2	9
166	Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. <i>ESMO Open</i> , 2021, 6, 100300.	2.0	9
167	Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1153-1161.	1.3	8
168	Reply to the letter to the editor "Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?" by Rodriguez-Wallberg et al.. <i>Annals of Oncology</i> , 2016, 27, 548-549.	0.6	8
169	News on the medical treatment of young women with early-stage HER2-negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1643-1655.	0.9	8
170	Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?. <i>ESMO Open</i> , 2018, 3, e000350.	2.0	8
171	Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy (CT) as a strategy to reduce ovarian failure in early breast cancer (BC) patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 105-105.	0.8	8
172	Treatment with aromatase inhibitors and markers of cardiovascular disease. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 261-267.	1.1	7
173	Is HER2-positive metastatic breast cancer still an incurable disease?. <i>Lancet Oncology</i> , The, 2020, 21, 471-472.	5.1	7
174	Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492093181.	0.6	7
175	Impact of ARTs on oncological outcomes in young breast cancer survivors. <i>Human Reproduction</i> , 2021, 36, 381-389.	0.4	7
176	Oncofertility and COVID-19" cancer does not wait. <i>Ecancermedicalscience</i> , 2020, 14, ed101.	0.6	7
177	Risk of gonadotoxicity with immunotherapy and targeted agents remains an unsolved but crucial issue. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13779.	1.7	7
178	Fertility preservation inBRCA-mutated breast cancer patients. <i>Breast Cancer Management</i> , 2016, 5, 61-68.	0.2	6
179	Another step towards improving oncofertility counselling of young women with Hodgkin's lymphoma. <i>Lancet Oncology</i> , The, 2018, 19, 1264-1266.	5.1	6
180	Reply to V. Turan et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 86-88.	0.8	6

#	ARTICLE	IF	CITATIONS
181	New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open" Cancer Horizons Series. <i>ESMO Open</i> , 2019, 4, e000501.	2.0	6
182	Tumor-to-nipple Distance Should Not Preclude Nipple-sparing Mastectomy in Breast Cancer Patients. Personal Experience and Literature Review. <i>Anticancer Research</i> , 2020, 40, 3543-3550.	0.5	6
183	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. <i>European Journal of Cancer</i> , 2020, 136, 43-51.	1.3	6
184	Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 241-250.	1.1	6
185	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 82.	2.3	6
186	Oncofertility counselling in premenopausal women with HER2-positive breast cancer. <i>Oncotarget</i> , 2019, 10, 926-929.	0.8	6
187	De novo metastatic breast cancer arising in young women: review of the current evidence. <i>Clinical Breast Cancer</i> , 2021, , .	1.1	6
188	Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer. <i>JCO Global Oncology</i> , 2022, 8, e2100153.	0.8	6
189	Installing oncofertility programs for breast cancer in limited versus optimum resource settings: Empirical data from 39 surveyed centers in Repro-Can-OPEN Study Part I & II. <i>Journal of Assisted Reproduction and Genetics</i> , 2022, 39, 505-516.	1.2	6
190	Contraception and Hormone Replacement Therapy in Healthy Carriers of Germline BRCA1/2 Genes Pathogenic Variants: Results from an Italian Survey. <i>Cancers</i> , 2022, 14, 3457.	1.7	6
191	Progesterone Receptor Status and Clinical Outcome in Breast Cancer Patients with Estrogen Receptor-Positive Locoregional Recurrence. <i>Tumori</i> , 2015, 101, 398-403.	0.6	5
192	Implementing the hub and spoke model for the oncofertility units. <i>Breast</i> , 2019, 48, 100.	0.9	5
193	Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 43-51.	1.1	5
194	Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study. <i>ESMO Open</i> , 2020, 5, e000719.	2.0	5
195	Muscle mass loss after neoadjuvant chemotherapy in breast cancer: estimation on breast magnetic resonance imaging using pectoralis muscle area. <i>European Radiology</i> , 2020, 30, 4234-4241.	2.3	5
196	Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 149, 102940.	2.0	5
197	Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 686625.	1.3	5
198	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110534.	1.4	5

#	ARTICLE	IF	CITATIONS
199	Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study. <i>Oncotarget</i> , 2017, 8, 44800-44810.	0.8	4
200	Pregnancies in young women with diagnosis and treatment of HER2-positive breast cancer. <i>Oncotarget</i> , 2019, 10, 803-804.	0.8	4
201	Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 273-282.	1.1	4
202	Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 457-462.	1.1	4
203	Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene. <i>Scientific Reports</i> , 2022, 12, 1658.	1.6	4
204	Breast Cancer Patients' Experience and Wishes Regarding Communication on Sexual Health: The BEROSE Study. <i>Cancer Investigation</i> , 2022, 40, 483-493.	0.6	4
205	Get up, stand up: Alongside adolescents and young adults with cancer for their right to be forgotten. <i>Tumori</i> , 2022, 108, 402-406.	0.6	4
206	Letrozole withdrawal response in locally advanced breast cancer. <i>Annals of Oncology</i> , 2011, 22, 1927-1928.	0.6	3
207	Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?. <i>European Journal of Cancer</i> , 2016, 54, 163-164.	1.3	3
208	Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 245-246.	1.1	3
209	Call for assessing treatment-induced gonadotoxicity of platinum-based chemotherapy in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 239-240.	1.1	3
210	Moving trastuzumab emtansine (T-DM1) to the early setting of breast cancer treatment. <i>Annals of Palliative Medicine</i> , 2020, 9, 512-516.	0.5	3
211	Cyclophosphamide-Free Adjuvant Chemotherapy for the Potential Prevention of Premature Ovarian Insufficiency and Infertility in Young Women With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1274-1276.	3.0	3
212	Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 341-351.	1.0	3
213	What Medical Oncologist Residents Think about the Italian Speciality Schools: A Survey of the Italian Association of Medical Oncology (AIOM) on Educational, Clinical and Research Activities. <i>PLoS ONE</i> , 2016, 11, e0159146.	1.1	3
214	Fertility issues in young breast cancer patients: what women want. <i>Journal of Thoracic Disease</i> , 2014, 6, 584-8.	0.6	3
215	Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1117-1126.	3.0	3
216	Adjuvant hormonal therapy in young breast cancer patients. <i>Breast Cancer Management</i> , 2014, 3, 1-4.	0.2	2

#	ARTICLE	IF	CITATIONS
217	Cyclin-dependent kinase (CDK) inhibitors for hormone receptor-positive advanced breast cancer. The Cochrane Library, 2018, , .	1.5	2
218	Response. Journal of the National Cancer Institute, 2018, 110, 919-920.	3.0	2
219	Adherence to Guidelines in Requesting Oncotype DX in a Publicly Funded Health Care System. Current Oncology, 2018, 25, 311-318.	0.9	2
220	Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial. ESMO Open, 2020, 5, e000979.	2.0	2
221	Reply to S. A. Narod et al. Journal of Clinical Oncology, 2020, 38, 4352-4354.	0.8	2
222	Breast cancer screening of mutation carriers in the era of COVID-19 pandemic. International Journal of Cancer, 2020, 147, 3574-3575.	2.3	2
223	Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial. European Journal of Cancer, 2021, 144, 351-359.	1.3	2
224	Final analysis of the PROMISE-GIM6 phase III trial assessing GnRH agonist use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer.. Journal of Clinical Oncology, 2021, 39, 516-516.	0.8	2
225	Response to letter entitled: Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. European Journal of Cancer, 2021, 155, 303-306.	1.3	2
226	Breast Cancer Surgery in the COVID-19 Pandemic: Validation of a Preventive Program for Patients and Health Care Workers. In Vivo, 2021, 35, 635-639.	0.6	2
227	Update on Pregnancy Following Breast Cancer Diagnosis and Treatment. Cancer Journal (Sudbury,) Tj ETQq1 1 0.784314 rgBJ /Overlock	1.0	2
228	1957 Ovarian suppression with luteinizing hormone-releasing hormone agonists during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients: A systematic review and meta-analysis of randomized studies. European Journal of Cancer, 2015, 51, S318-S319.	1.3	1
229	The BCY3/BCC 2017 survey on physiciansâ€™ knowledge, attitudes and practice towards fertility and pregnancy issues in young breast cancer patients. European Journal of Cancer, 2018, 92, S22.	1.3	1
230	Reply to the letter â€œSafety of fertility preservation in women with breast cancerâ€. Breast, 2019, 43, 149-150.	0.9	1
231	The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC).. Journal of Clinical Oncology, 2021, 39, 524-524.	0.8	1
232	Fertility Preservation and Pregnancy After Breast Cancer. , 2020, , 167-176.		1
233	Pyrotinib: a new promising targeted agent for human epidermal growth factor receptor 2-positive breast cancer. Translational Breast Cancer Research, 0, 1, 11-11.	0.4	1
234	What is the role of HER2-specific antibody immunity in patients with HER2-positive early breast cancer receiving chemotherapy plus trastuzumab?. Translational Cancer Research, 2018, 7, 1354-1356.	0.4	1

#	ARTICLE	IF	CITATIONS
235	Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial. <i>Tumori</i> , 2022, , 030089162110675.	0.6	1
236	Abstract P1-18-11: Analysis of first-line (1L) patients (pts) with de novo disease vs late relapse and all pts with vs without prior chemotherapy (CT) in the MONALEESA-3 (ML-3) trial. <i>Cancer Research</i> , 2022, 82, P1-18-11-P1-18-11.	0.4	1
237	Editorial: Breast Cancer in Young Women: Dedicated Research Efforts Are Needed. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
238	P-464 Long-acting GnRH agonist ovulation trigger to avoid ovarian hyperstimulation and to combine oocyte cryopreservation with ovarian suppression during chemotherapy. <i>Human Reproduction</i> , 2022, 37, .	0.4	1
239	Breast Cancer in Special Groups: Breast Cancer in Pregnancy. , 2018, , 511-520.		0
240	Fertility Preservation in Women with Breast Cancer. , 2018, , 521-527.		0
241	ESMO Leaders Generation Programme: an alumni insight. <i>ESMO Open</i> , 2018, 3, e000312.	2.0	0
242	Reply to the letter "Body mass index and clinical outcomes in trastuzumab-treated metastatic breast cancer patients: An alternative explanation for the lack of association". <i>Breast</i> , 2018, 39, 151-152.	0.9	0
243	Highlights from ABC5: Bridging the Gap. <i>Breast Care</i> , 2020, 15, 75-81.	0.8	0
244	ESMO Open: news in breast cancer 2019. <i>ESMO Open</i> , 2020, 5, e000794.	2.0	0
245	Highlights from the San Antonio Breast Cancer Symposium (SABCS) 2019. <i>Breast Care</i> , 2020, 15, 192-196.	0.8	0
246	ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer. <i>ESMO Open</i> , 2021, 6, 100014.	2.0	0
247	ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib. <i>ESMO Open</i> , 2021, 6, 100018.	2.0	0
248	Use of GnRH Analogs for Prevention of Chemotherapy-Induced Gonadotoxicity. , 2021, , 171-181.		0
249	Fertility Issues in Patients with Breast Cancer or Survivors. , 2017, , 729-737.		0
250	ESMO Open special series on new emerging targets in cancer immunotherapy. <i>ESMO Open</i> , 2019, 4, e000795.	2.0	0
251	Fertility and Pregnancy Counseling of Breast Cancer Patients with Germline BRCA Mutations. , 2020, , 131-147.		0
252	A retrospective study evaluating the impact of scattering radiation from imaging procedures on oocyte quality during ovarian stimulation for fertility preservation in young breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 123-130.	1.1	0

#	ARTICLE	IF	CITATIONS
253	Abstract PD5-06: Safety of assisted reproductive technologies (ART) following treatment completion in young women with germline <i>BRCA</i> pathogenic variants having a pregnancy after breast cancer. <i>Cancer Research</i> , 2022, 82, PD5-06-PD5-06.	0.4	0
254	Abstract P3-09-03: Single nucleotide polymorphisms of aromatase gene ( <i>CYP19A1</i> ) and toxicity of adjuvant aromatase inhibitors: A translational, prospective study. <i>Cancer Research</i> , 2022, 82, P3-09-03-P3-09-03.	0.4	0
255	Comment on "Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis". <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0